What is antibiotic de-escalation?

• A. Starting broad-spectrum therapy for all suspected infections
• B. Narrowing therapy to culture-guided or narrower-spectrum agents; reduces resistance, toxicity, and costs
• C. Switching to antiviral therapy
• D. Increasing dose to overcome resistance

Answer: (B)

Antibiotic de-escalation means starting with broad-spectrum therapy to cover the likely pathogens, then switching to a narrower, culture-guided antibiotic once results and the patient’s condition are known. The goal is to tailor therapy to the specific organism and its susceptibilities, rather than continuing broad coverage longer than needed.

Why this choice fits best: using a narrower or targeted antibiotic after culture data are available reduces the selective pressure that drives resistance, lowers the risk of adverse effects and toxicity, and often decreases costs. It preserves potent antibiotics for when they’re truly necessary and minimizes unnecessary exposure of the patient’s normal flora to broad-spectrum agents.

Context helps: you begin with empiric therapy because you don’t know the exact pathogen yet, but once labs identify the organism and susceptibilities, you switch to the most specific drug that will effectively treat that organism. If the infection is viral or no antibiotic is needed, de-escalation isn’t applicable. Increasing the dose to overcome resistance is a different, escalation-focused strategy, not de-escalation.